Catalyst Pharm Inc (CPRX)

$31.49 +0.01 (0.03%)
Market Cap 3.85B
Revenue (ttm) 588.99M
Net Income (ttm) 214.33M
EPS (ttm) N/A
PE Ratio 11.92
Forward PE 11.92
Profit Margin 36.39%
Debt to Equity Ratio 0.00
Volume 15,513,700
Avg Vol 2,707,952
Day's Range N/A - N/A
Shares Out 122.42M
Stochastic %K 80%
Beta 0.74
Analysts Sell
Price Target $32.80

Company Profile

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well...

Industry: Biotechnology
Sector: Healthcare
Phone: 305 420 3200
Address:
355 Alhambra Circle, Suite 801, Coral Gables, United States
Splashavelle
Splashavelle Jul. 15 at 6:29 AM
$CPRX what happened I don't see us on rh
0 · Reply
StocktwitsNews
StocktwitsNews Jul. 10 at 12:02 AM
SEI Stock Jumps 5% After-Hours As S&P 600 Inclusion Sparks Buying $SEI $CPRX https://stocktwits.com/news/equity/markets/sei-stock-jumps-after-hours-as-sandp-600-inclusions-sparks-buying/cZmAZYNR7Fc
0 · Reply
pcstock12
pcstock12 Jul. 9 at 2:43 PM
$CPRX when the buyout will happen?
0 · Reply
Mergerbrief
Mergerbrief Jul. 8 at 11:55 AM
$CPRX / Angelini Pharma – Shareholder Vote $CPRX
0 · Reply
STONER_Smurf
STONER_Smurf Jul. 6 at 11:41 PM
$CPRX this keeps heading higher and higher. Fuck I never got in at when it was sub 10 LOL I wished you boys good luck a few times over the last couple years and it keep going. Congrats , nice steady as she goes
1 · Reply
pcstock12
pcstock12 Jun. 20 at 12:43 AM
$CPRX did anyone receive anything about the virtual meeting to vote on the merger?
0 · Reply
pcstock12
pcstock12 Jun. 20 at 12:39 AM
$CPRX https://www.stocktitan.net/sec-filings/CPRX/defm14a-catalyst-pharmaceuticals-inc-merger-proxy-statement-91233ea639e8.html
0 · Reply
BioTechHealthX
BioTechHealthX Jun. 14 at 4:08 PM
$CPRX Catalyst Pharmaceuticals (CPRX) may not be the wildest biotech name on Wall Street, but that may be its biggest advantage. With profits, revenue, and rare disease exposure, this small-cap healthcare stock offers a more stable twist on biotech investing. https://biotechhealthx.com/biotech-news/is-catalyst-pharmaceuticals-cprx-a-smart-rare-disease-stock-to-buy-for-long-term-growth/
0 · Reply
Jjuicy8
Jjuicy8 Jun. 13 at 2:31 AM
$CPRX I bought 53 at 2.40 in 2018, should I sell now??
1 · Reply
BioTechHealthX
BioTechHealthX Jun. 12 at 9:49 AM
$ARQT $AUPH $CPRX $OCUL $TRVI From cancer cell therapy to rare disease treatments and eye-disease breakthroughs, these small-cap biotech stocks are chasing major medical markets. Here are 10 biotech companies drawing attention for their pipelines, revenue growth, and upside potential. https://biotechhealthx.com/biotech-news/top-5-small-cap-biotech-stocks-that-could-surge-100/
0 · Reply
Latest News on CPRX
Solaris to replace Catalyst Pharmaceuticals in the S&P 600 at open on 7/15

2026-07-09T21:20:17.000Z - 5 days ago

Solaris to replace Catalyst Pharmaceuticals in the S&P 600 at open on 7/15

SEI

Catalyst Pharmaceuticals Transcript: EGM 2026

Jul 8, 2026, 9:00 AM EDT - 6 days ago

Catalyst Pharmaceuticals Transcript: EGM 2026

Vamorolone Demonstrates On-Target Glucocorticoid Activity Without the Immunosuppression Characteristic of Traditional Corticosteroids at Clinical Doses

Jun 30, 2026, 8:03 AM EDT - 14 days ago

Vamorolone Demonstrates On-Target Glucocorticoid Activity Without the Immunosuppression Characteristic of Traditional Corticosteroids at Clinical Doses

Catalyst Pharmaceuticals Proxy statement: Proxy filing

Jun 30, 2026, 8:00 AM EDT - 14 days ago

Catalyst Pharmaceuticals Proxy statement: Proxy filing

Catalyst Pharmaceuticals Proxy statement: Proxy filing

Jun 8, 2026, 8:00 AM EDT - 5 weeks ago

Catalyst Pharmaceuticals Proxy statement: Proxy filing

Catalyst Pharmaceuticals downgraded to Neutral from Buy at H.C. Wainwright

2026-05-28T16:51:04.000Z - 6 weeks ago

Catalyst Pharmaceuticals downgraded to Neutral from Buy at H.C. Wainwright

Catalyst Pharmaceuticals Proxy statement: Proxy filing

May 28, 2026, 8:00 AM EDT - 6 weeks ago

Catalyst Pharmaceuticals Proxy statement: Proxy filing

Catalyst Pharmaceuticals Proxy statement: Proxy filing

May 12, 2026, 8:00 AM EDT - 2 months ago

Catalyst Pharmaceuticals Proxy statement: Proxy filing

Catalyst Pharmaceuticals reports Q1 non-GAAP EPS 79c, consensus 64c

2026-05-11T23:59:59.000Z - 2 months ago

Catalyst Pharmaceuticals reports Q1 non-GAAP EPS 79c, consensus 64c

Catalyst Pharmaceuticals not providing forward-looking guidance

2026-05-11T23:57:03.000Z - 2 months ago

Catalyst Pharmaceuticals not providing forward-looking guidance

Catalyst Pharmaceuticals Reports First Quarter 2026 Financial Results

May 11, 2026, 4:12 PM EDT - 2 months ago

Catalyst Pharmaceuticals Reports First Quarter 2026 Financial Results

Catalyst Pharmaceuticals Quarterly report: Q1 2026

May 11, 2026, 4:00 PM EDT - 2 months ago

Catalyst Pharmaceuticals Quarterly report: Q1 2026

Catalyst Pharmaceuticals Earnings release: Q1 2026

May 11, 2026, 4:00 PM EDT - 2 months ago

Catalyst Pharmaceuticals Earnings release: Q1 2026

Catalyst Pharmaceuticals downgraded to Neutral from Buy at Citi

2026-05-08T22:11:48.000Z - 2 months ago

Catalyst Pharmaceuticals downgraded to Neutral from Buy at Citi

Catalyst Pharmaceuticals Proxy statement: Proxy filing

May 8, 2026, 8:00 AM EDT - 2 months ago

Catalyst Pharmaceuticals Proxy statement: Proxy filing

Catalyst Pharmaceuticals Cancels First Quarter 2026 Conference Call and Webcast

May 7, 2026, 4:02 PM EDT - 2 months ago

Catalyst Pharmaceuticals Cancels First Quarter 2026 Conference Call and Webcast

Catalyst Pharmaceuticals downgraded to Neutral from Outperform at Baird

2026-05-07T17:26:23.000Z - 2 months ago

Catalyst Pharmaceuticals downgraded to Neutral from Outperform at Baird

Catalyst Pharmaceuticals downgraded to Perform from Outperform at Oppenheimer

2026-05-07T17:16:59.000Z - 2 months ago

Catalyst Pharmaceuticals downgraded to Perform from Outperform at Oppenheimer

Catalyst Pharmaceuticals downgraded to Equal Weight from Overweight at Stephens

2026-05-07T13:04:41.000Z - 2 months ago

Catalyst Pharmaceuticals downgraded to Equal Weight from Overweight at Stephens

Catalyst Pharmaceuticals to be acquired by Angelini Pharma for $31.50 per share

2026-05-07T12:07:05.000Z - 2 months ago

Catalyst Pharmaceuticals to be acquired by Angelini Pharma for $31.50 per share

BX

Catalyst Pharmaceuticals Proxy statement: Proxy filing

May 7, 2026, 8:00 AM EDT - 2 months ago

Catalyst Pharmaceuticals Proxy statement: Proxy filing

Catalyst Pharmaceuticals Proxy statement: Proxy filing

May 7, 2026, 8:00 AM EDT - 2 months ago

Catalyst Pharmaceuticals Proxy statement: Proxy filing

Catalyst Pharma to Be Acquired by Angelini Pharma in $4.1 Billion Deal

May 7, 2026, 3:15 AM EDT - 2 months ago

Catalyst Pharma to Be Acquired by Angelini Pharma in $4.1 Billion Deal

Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Hetero Labs Ltd.

May 7, 2026, 2:44 AM EDT - 2 months ago

Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Hetero Labs Ltd.

Italy's Angelini Pharma to buy Catalyst Pharmaceuticals for $4.1 billion

May 7, 2026, 2:24 AM EDT - 2 months ago

Italy's Angelini Pharma to buy Catalyst Pharmaceuticals for $4.1 billion

Angelini Pharma to Acquire Catalyst Pharmaceuticals for 4.1 Billion USD (3.5 Billion Euros), Entering the U.S. Market and Consolidating its Leadership in Brain Health and Rare Disease

May 7, 2026, 2:14 AM EDT - 2 months ago

Angelini Pharma to Acquire Catalyst Pharmaceuticals for 4.1 Billion USD (3.5 Billion Euros), Entering the U.S. Market and Consolidating its Leadership in Brain Health and Rare Disease

Catalyst Pharmaceuticals to Report First Quarter 2026 Financial Results on May 11, 2026

Apr 28, 2026, 8:03 AM EDT - 2 months ago

Catalyst Pharmaceuticals to Report First Quarter 2026 Financial Results on May 11, 2026

Angelini exploring acquisition of Catalyst Pharmaceuticals, Bloomberg says

2026-04-27T20:17:56.000Z - 2 months ago

Angelini exploring acquisition of Catalyst Pharmaceuticals, Bloomberg says

Catalyst Pharmaceuticals trading resumes

2026-04-27T16:10:16.000Z - 2 months ago

Catalyst Pharmaceuticals trading resumes

Catalyst Pharmaceuticals trading halted, volatility trading pause

2026-04-27T16:06:36.000Z - 2 months ago

Catalyst Pharmaceuticals trading halted, volatility trading pause

See How Institutions Boost Catalyst Shares

Apr 15, 2026, 7:33 AM EDT - 3 months ago

See How Institutions Boost Catalyst Shares

Catalyst Pharmaceuticals Transcript: Barclays 28th Annual Global Healthcare Conference

Mar 10, 2026, 3:30 PM EDT - 4 months ago

Catalyst Pharmaceuticals Transcript: Barclays 28th Annual Global Healthcare Conference

Catalyst Pharmaceuticals to Showcase Real‑World Findings in Duchenne Muscular Dystrophy and Host Vamorolone-Focused Symposium at the 2026 MDA Clinical & Scientific Conference

Mar 6, 2026, 8:03 AM EST - 4 months ago

Catalyst Pharmaceuticals to Showcase Real‑World Findings in Duchenne Muscular Dystrophy and Host Vamorolone-Focused Symposium at the 2026 MDA Clinical & Scientific Conference

Catalyst Pharmaceuticals price target raised to $35 from $33 at Citi

2026-03-03T10:40:36.000Z - 4 months ago

Catalyst Pharmaceuticals price target raised to $35 from $33 at Citi

Catalyst Pharmaceuticals Earnings Call Transcript: Q4 2025

Feb 26, 2026, 8:30 AM EST - 4 months ago

Catalyst Pharmaceuticals Earnings Call Transcript: Q4 2025

Catalyst Pharmaceuticals Earnings release: Q4 2025

Feb 26, 2026, 8:30 AM EST - 4 months ago

Catalyst Pharmaceuticals Earnings release: Q4 2025

Catalyst Pharmaceuticals Annual report: Q4 2025

Feb 26, 2026, 8:30 AM EST - 4 months ago

Catalyst Pharmaceuticals Annual report: Q4 2025

Catalyst Pharmaceuticals reports Q4 EPS 68c, consensus 50c

2026-02-25T22:08:41.000Z - 4 months ago

Catalyst Pharmaceuticals reports Q4 EPS 68c, consensus 50c

Catalyst Pharmaceuticals sees FY26 revenue $615M-$645M, consensus $615.58M

2026-02-25T22:07:58.000Z - 4 months ago

Catalyst Pharmaceuticals sees FY26 revenue $615M-$645M, consensus $615.58M

Catalyst Pharmaceuticals Reports Record Fourth Quarter and Record Full Year 2025 Financial Results and Provides 2026 Financial Guidance

Feb 25, 2026, 4:07 PM EST - 4 months ago

Catalyst Pharmaceuticals Reports Record Fourth Quarter and Record Full Year 2025 Financial Results and Provides 2026 Financial Guidance

Catalyst Pharmaceuticals to Participate in the Barclays 28th Annual Global Healthcare Conference

Feb 24, 2026, 8:03 AM EST - 5 months ago

Catalyst Pharmaceuticals to Participate in the Barclays 28th Annual Global Healthcare Conference

Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026

Feb 11, 2026, 8:03 AM EST - 5 months ago

Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026

Catalyst Pharmaceuticals Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 6:45 PM EST - 6 months ago

Catalyst Pharmaceuticals Transcript: 44th Annual J.P. Morgan Healthcare Conference

Catalyst Pharmaceuticals Slides: Corporate presentation

Jan 12, 2026, 7:00 AM EST - 6 months ago

Catalyst Pharmaceuticals Slides: Corporate presentation

Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2026 List of America's Most Successful Small-Cap Companies

Jan 8, 2026, 8:03 AM EST - 6 months ago

Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2026 List of America's Most Successful Small-Cap Companies

Catalyst Pharmaceuticals to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Dec 15, 2025, 8:03 AM EST - 7 months ago

Catalyst Pharmaceuticals to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Catalyst Pharmaceuticals Transcript: BofA Securities CNS Therapeutics Virtual Conference 2025

Dec 8, 2025, 12:35 PM EST - 7 months ago

Catalyst Pharmaceuticals Transcript: BofA Securities CNS Therapeutics Virtual Conference 2025

Catalyst Pharmaceuticals Transcript: Citi Annual Global Healthcare Conference 2025

Dec 2, 2025, 1:00 PM EST - 8 months ago

Catalyst Pharmaceuticals Transcript: Citi Annual Global Healthcare Conference 2025

Catalyst Pharmaceuticals to Participate in the Bank of America CNS Therapeutics Virtual Conference

Nov 24, 2025, 8:03 AM EST - 8 months ago

Catalyst Pharmaceuticals to Participate in the Bank of America CNS Therapeutics Virtual Conference

Catalyst Pharmaceuticals Recognized as One of North America's Fastest-Growing Companies on the 2025 Deloitte Technology Fast 500™

Nov 19, 2025, 8:03 AM EST - 8 months ago

Catalyst Pharmaceuticals Recognized as One of North America's Fastest-Growing Companies on the 2025 Deloitte Technology Fast 500™

Catalyst Pharmaceuticals to Participate in Citi's 2025 Global Healthcare Conference

Nov 18, 2025, 8:03 AM EST - 8 months ago

Catalyst Pharmaceuticals to Participate in Citi's 2025 Global Healthcare Conference

Catalyst Pharmaceuticals Transcript: Jefferies London Healthcare Conference 2025

Nov 17, 2025, 9:00 AM EST - 8 months ago

Catalyst Pharmaceuticals Transcript: Jefferies London Healthcare Conference 2025

Catalyst Pharmaceuticals price target raised to $33 from $32 at Oppenheimer

2025-11-07T13:37:13.000Z - 8 months ago

Catalyst Pharmaceuticals price target raised to $33 from $32 at Oppenheimer

Catalyst Pharmaceuticals price target raised to $33 from $31 at Citi

2025-11-07T11:10:34.000Z - 8 months ago

Catalyst Pharmaceuticals price target raised to $33 from $31 at Citi

Catalyst Pharmaceuticals Earnings Call Transcript: Q3 2025

Nov 6, 2025, 8:30 AM EST - 8 months ago

Catalyst Pharmaceuticals Earnings Call Transcript: Q3 2025

Catalyst Pharmaceuticals Earnings release: Q3 2025

Nov 6, 2025, 8:30 AM EST - 8 months ago

Catalyst Pharmaceuticals Earnings release: Q3 2025

Catalyst Pharmaceuticals Quarterly report: Q3 2025

Nov 6, 2025, 8:30 AM EST - 8 months ago

Catalyst Pharmaceuticals Quarterly report: Q3 2025

Catalyst Pharmaceuticals reports Q3 EPS 68c, consensus 54c

2025-11-05T22:45:34.000Z - 8 months ago

Catalyst Pharmaceuticals reports Q3 EPS 68c, consensus 54c

Catalyst Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 5, 2025, 4:06 PM EST - 8 months ago

Catalyst Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

Catalyst Pharmaceuticals Recognized Among BioSpace 2026 Best Places to Work

Nov 4, 2025, 4:03 PM EST - 9 months ago

Catalyst Pharmaceuticals Recognized Among BioSpace 2026 Best Places to Work

Catalyst Pharmaceuticals to Participate in Jefferies Global Healthcare Conference

Nov 3, 2025, 8:03 AM EST - 9 months ago

Catalyst Pharmaceuticals to Participate in Jefferies Global Healthcare Conference

Catalyst Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 5, 2025

Oct 22, 2025, 8:03 AM EDT - 9 months ago

Catalyst Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 5, 2025

Catalyst Pharmaceuticals Announces Presentations at Upcoming Scientific Conferences

Oct 9, 2025, 8:03 AM EDT - 9 months ago

Catalyst Pharmaceuticals Announces Presentations at Upcoming Scientific Conferences

Catalyst Pharmaceuticals announces $200M share repurchase program

2025-10-01T12:20:12.000Z - 10 months ago

Catalyst Pharmaceuticals announces $200M share repurchase program

Catalyst Pharmaceuticals Announces $200 Million Share Repurchase Program

Oct 1, 2025, 8:03 AM EDT - 10 months ago

Catalyst Pharmaceuticals Announces $200 Million Share Repurchase Program

Catalyst Pharmaceuticals Transcript: Baird Global Healthcare Conference 2025

Sep 9, 2025, 12:50 PM EDT - 11 months ago

Catalyst Pharmaceuticals Transcript: Baird Global Healthcare Conference 2025

Catalyst Pharmaceuticals Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 8, 2025, 9:00 AM EDT - 11 months ago

Catalyst Pharmaceuticals Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Catalyst Pharmaceuticals Transcript: Cantor Global Healthcare Conference 2025

Sep 4, 2025, 3:20 PM EDT - 11 months ago

Catalyst Pharmaceuticals Transcript: Cantor Global Healthcare Conference 2025

Catalyst Pharmaceuticals Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Sep 3, 2025, 2:15 PM EDT - 11 months ago

Catalyst Pharmaceuticals Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences

Aug 28, 2025, 8:03 AM EDT - 11 months ago

Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences

UPDATED- Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Lupin Pharmaceuticals

Aug 26, 2025, 7:12 PM EDT - 11 months ago

UPDATED- Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Lupin Pharmaceuticals

Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Lupin Pharmaceuticals

Aug 25, 2025, 8:03 AM EDT - 11 months ago

Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Lupin Pharmaceuticals

Catalyst Pharmaceuticals Earnings Call Transcript: Q2 2025

Aug 7, 2025, 8:30 AM EDT - 1 year ago

Catalyst Pharmaceuticals Earnings Call Transcript: Q2 2025

Catalyst Pharmaceuticals Earnings release: Q2 2025

Aug 7, 2025, 8:30 AM EDT - 1 year ago

Catalyst Pharmaceuticals Earnings release: Q2 2025

Catalyst Pharmaceuticals Quarterly report: Q2 2025

Aug 7, 2025, 8:30 AM EDT - 1 year ago

Catalyst Pharmaceuticals Quarterly report: Q2 2025

Catalyst Pharmaceuticals Reports Record Second Quarter and First Half 2025 Financial Results; Provides Business Update

Aug 6, 2025, 4:13 PM EDT - 1 year ago

Catalyst Pharmaceuticals Reports Record Second Quarter and First Half 2025 Financial Results; Provides Business Update

Lambert Eaton Myasthenic Syndrome (LEMS) Antibody Testing and Treatment Recommendations Added to NCCN Clinical Practice Guidelines for Small Cell Lung Cancer (SCLC)

Aug 6, 2025, 8:03 AM EDT - 1 year ago

Lambert Eaton Myasthenic Syndrome (LEMS) Antibody Testing and Treatment Recommendations Added to NCCN Clinical Practice Guidelines for Small Cell Lung Cancer (SCLC)

Catalyst Pharmaceuticals Appoints Daniel Curran, MD, to its Board of Directors

Aug 4, 2025, 8:03 AM EDT - 1 year ago

Catalyst Pharmaceuticals Appoints Daniel Curran, MD, to its Board of Directors

Catalyst Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 6, 2025

Jul 22, 2025, 8:03 AM EDT - 1 year ago

Catalyst Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 6, 2025

Strong Inflows Make Catalyst Stock an Outlier

Jun 11, 2025, 7:08 AM EDT - 1 year ago

Strong Inflows Make Catalyst Stock an Outlier

20 stocks you should avoid — no matter how well the market does

Jun 11, 2025, 7:00 AM EDT - 1 year ago

20 stocks you should avoid — no matter how well the market does

CORT CRK CRNC DDD LUMN LYV MGPI

Catalyst Pharmaceuticals Announces Appointment of William T. Andrews, MD, FACP as Chief Medical Officer

Jun 2, 2025, 8:03 AM EDT - 1 year ago

Catalyst Pharmaceuticals Announces Appointment of William T. Andrews, MD, FACP as Chief Medical Officer

Catalyst Pharmaceuticals Transcript: Bank of America 2025 Healthcare Conference

May 14, 2025, 11:00 AM EDT - 1 year ago

Catalyst Pharmaceuticals Transcript: Bank of America 2025 Healthcare Conference

Catalyst Pharmaceuticals Slides: Corporate Presentation

May 12, 2025, 2:00 AM EDT - 1 year ago

Catalyst Pharmaceuticals Slides: Corporate Presentation

Catalyst Pharmaceuticals Earnings Call Transcript: Q1 2025

May 8, 2025, 8:30 AM EDT - 1 year ago

Catalyst Pharmaceuticals Earnings Call Transcript: Q1 2025

Catalyst Pharmaceuticals Earnings release: Q1 2025

May 8, 2025, 8:30 AM EDT - 1 year ago

Catalyst Pharmaceuticals Earnings release: Q1 2025

Catalyst Pharmaceuticals Quarterly report: Q1 2025

May 8, 2025, 8:30 AM EDT - 1 year ago

Catalyst Pharmaceuticals Quarterly report: Q1 2025

Catalyst Pharmaceuticals Reports Record First Quarter 2025 Financial Results and Provides Business Update

May 7, 2025, 4:14 PM EDT - 1 year ago

Catalyst Pharmaceuticals Reports Record First Quarter 2025 Financial Results and Provides Business Update

Catalyst Pharmaceuticals to Participate in the BofA Securities Health Care Conference 2025

Apr 30, 2025, 8:03 AM EDT - 1 year ago

Catalyst Pharmaceuticals to Participate in the BofA Securities Health Care Conference 2025

Catalyst Pharmaceuticals to Report First Quarter 2025 Financial Results on May 7, 2025

Apr 22, 2025, 8:03 AM EDT - 1 year ago

Catalyst Pharmaceuticals to Report First Quarter 2025 Financial Results on May 7, 2025

Catalyst Pharmaceuticals Proxy statement: Proxy Filing

Apr 11, 2025, 8:00 AM EDT - 1 year ago

Catalyst Pharmaceuticals Proxy statement: Proxy Filing

Catalyst Pharmaceuticals Announces Health Canada's Acceptance of AGAMREE® New Drug Submission with Priority Review for Sub-Licensee Kye Pharmaceuticals

Apr 8, 2025, 8:06 AM EDT - 1 year ago

Catalyst Pharmaceuticals Announces Health Canada's Acceptance of AGAMREE® New Drug Submission with Priority Review for Sub-Licensee Kye Pharmaceuticals

Strong Revenue, Drug Performance Lift Catalyst Shares

Mar 26, 2025, 8:12 AM EDT - 1 year ago

Strong Revenue, Drug Performance Lift Catalyst Shares

Catalyst Pharmaceuticals Transcript: Barclays 27th Annual Global Healthcare Conference

Mar 11, 2025, 1:00 PM EDT - 1 year ago

Catalyst Pharmaceuticals Transcript: Barclays 27th Annual Global Healthcare Conference

Catalyst Pharmaceuticals to Participate in the Barclays 27th Annual Global Healthcare Conference

Mar 4, 2025, 8:03 AM EST - 1 year ago

Catalyst Pharmaceuticals to Participate in the Barclays 27th Annual Global Healthcare Conference

Catalyst Pharmaceuticals Earnings Call Transcript: Q4 2024

Feb 27, 2025, 8:30 AM EST - 1 year ago

Catalyst Pharmaceuticals Earnings Call Transcript: Q4 2024

Catalyst Pharmaceuticals Earnings release: Q4 2024

Feb 27, 2025, 8:30 AM EST - 1 year ago

Catalyst Pharmaceuticals Earnings release: Q4 2024

Catalyst Pharmaceuticals Annual report: Q4 2024

Feb 27, 2025, 8:30 AM EST - 1 year ago

Catalyst Pharmaceuticals Annual report: Q4 2024

Catalyst Pharmaceuticals Reports Record Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Feb 26, 2025, 4:13 PM EST - 1 year ago

Catalyst Pharmaceuticals Reports Record Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2024 Financial Results on February 26, 2025

Feb 12, 2025, 8:03 AM EST - 1 year ago

Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2024 Financial Results on February 26, 2025

Catalyst Remains a Big Money Favorite

Feb 7, 2025, 3:56 PM EST - 1 year ago

Catalyst Remains a Big Money Favorite

Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2025 List of America's Most Successful Mid-Cap Companies

Jan 23, 2025, 8:03 AM EST - 1 year ago

Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2025 List of America's Most Successful Mid-Cap Companies

Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Launched FIRDAPSE® in Japan

Jan 21, 2025, 8:19 AM EST - 1 year ago

Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Launched FIRDAPSE® in Japan

Catalyst Pharmaceuticals Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 16, 2025, 1:30 PM EST - 1 year ago

Catalyst Pharmaceuticals Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Catalyst Pharmaceuticals Slides: FY 2025

Jan 16, 2025, 1:30 PM EST - 1 year ago

Catalyst Pharmaceuticals Slides: FY 2025

Catalyst Pharmaceuticals Slides: Corporate Presentation

Jan 13, 2025, 11:55 AM EST - 1 year ago

Catalyst Pharmaceuticals Slides: Corporate Presentation

Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Teva Pharmaceuticals

Jan 8, 2025, 12:30 PM EST - 1 year ago

Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Teva Pharmaceuticals

Catalyst Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 16, 2024, 8:03 AM EST - 1 year ago

Catalyst Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Splashavelle
Splashavelle Jul. 15 at 6:29 AM
$CPRX what happened I don't see us on rh
0 · Reply
StocktwitsNews
StocktwitsNews Jul. 10 at 12:02 AM
SEI Stock Jumps 5% After-Hours As S&P 600 Inclusion Sparks Buying $SEI $CPRX https://stocktwits.com/news/equity/markets/sei-stock-jumps-after-hours-as-sandp-600-inclusions-sparks-buying/cZmAZYNR7Fc
0 · Reply
pcstock12
pcstock12 Jul. 9 at 2:43 PM
$CPRX when the buyout will happen?
0 · Reply
Mergerbrief
Mergerbrief Jul. 8 at 11:55 AM
$CPRX / Angelini Pharma – Shareholder Vote $CPRX
0 · Reply
STONER_Smurf
STONER_Smurf Jul. 6 at 11:41 PM
$CPRX this keeps heading higher and higher. Fuck I never got in at when it was sub 10 LOL I wished you boys good luck a few times over the last couple years and it keep going. Congrats , nice steady as she goes
1 · Reply
pcstock12
pcstock12 Jun. 20 at 12:43 AM
$CPRX did anyone receive anything about the virtual meeting to vote on the merger?
0 · Reply
pcstock12
pcstock12 Jun. 20 at 12:39 AM
$CPRX https://www.stocktitan.net/sec-filings/CPRX/defm14a-catalyst-pharmaceuticals-inc-merger-proxy-statement-91233ea639e8.html
0 · Reply
BioTechHealthX
BioTechHealthX Jun. 14 at 4:08 PM
$CPRX Catalyst Pharmaceuticals (CPRX) may not be the wildest biotech name on Wall Street, but that may be its biggest advantage. With profits, revenue, and rare disease exposure, this small-cap healthcare stock offers a more stable twist on biotech investing. https://biotechhealthx.com/biotech-news/is-catalyst-pharmaceuticals-cprx-a-smart-rare-disease-stock-to-buy-for-long-term-growth/
0 · Reply
Jjuicy8
Jjuicy8 Jun. 13 at 2:31 AM
$CPRX I bought 53 at 2.40 in 2018, should I sell now??
1 · Reply
BioTechHealthX
BioTechHealthX Jun. 12 at 9:49 AM
$ARQT $AUPH $CPRX $OCUL $TRVI From cancer cell therapy to rare disease treatments and eye-disease breakthroughs, these small-cap biotech stocks are chasing major medical markets. Here are 10 biotech companies drawing attention for their pipelines, revenue growth, and upside potential. https://biotechhealthx.com/biotech-news/top-5-small-cap-biotech-stocks-that-could-surge-100/
0 · Reply
BigGainTom
BigGainTom Jun. 11 at 2:52 PM
$CPRX Is this company sold? Why such low amplitude of stock movements?
1 · Reply
StillWaiting101
StillWaiting101 Jun. 5 at 8:04 PM
$CPRX I miss the stability we had here, its scary out there right now lol
1 · Reply
DeMontoire
DeMontoire Jun. 3 at 12:15 PM
$CPRX is there a point on keeping any shares invested and wait for the closing in 6 months?
0 · Reply
pcstock12
pcstock12 May. 30 at 5:08 PM
$CPRX any update on shareholders votes on the buyout?
1 · Reply
beachlife
beachlife May. 28 at 10:55 PM
$CPRX can’t believe I went all in at 32.55. I can’t time nothing right🤪
0 · Reply
OnlyFibs
OnlyFibs May. 28 at 8:39 PM
RECAP 5/28 +Pos Comments: $ZS + Malcolm Ethridge $PUMP + Odeon Capital RECAP 5/28 -Neg Comments: $DLTR - Freedom Broker $CPRX - HC Wainwright $PHR - Piper Sandler
1 · Reply
OpenOutcrier
OpenOutcrier May. 28 at 8:00 PM
RECAP 5/28 +Pos Comments: $ZS + Malcolm Ethridge $PUMP + Odeon Capital RECAP 5/28 -Neg Comments: $DLTR - Freedom Broker $CPRX - HC Wainwright $PHR - Piper Sandler Live Breaking trading news www.openoutcrier.com
0 · Reply
StMichaelTwits
StMichaelTwits May. 21 at 8:20 PM
$CPRX What a beautiful chart. That April 2nd crossing of the 34 was an easy load day. 😘 👇🪇🕺
1 · Reply
maestro_38
maestro_38 May. 21 at 7:50 PM
$CPRX why does this keep creeping up now?
2 · Reply
DeMontoire
DeMontoire May. 18 at 3:07 PM
$CPRX a fair price to me would be $31.50 per share plus the approximate $7 they have in cash.
0 · Reply
WB_Bull
WB_Bull May. 14 at 4:23 PM
$CPRX I don't understand why big pharma don't make a better offer! the Angelini offer is too cheap! America first! 6 Billion at least!
0 · Reply
Gator123
Gator123 May. 14 at 4:08 PM
$CPRX management is selling this company very cheap. CPRX is not only making money also has a lot of cash at hand. I expect at least $9 B. A little bit disappointed.
0 · Reply